Sandoz Invites Young Entrepreneurs to Enter #SandozHACk, a Global Competition to Help Solve Healthcare Access Challenges

NovartisSandoz, the Novartis generic and biosimilar pharmaceutical division, announces the launch of Sandoz HACk - Healthcare Access Challenge - a global competition to generate innovative ideas and solutions to help tackle some of the world's most pressing healthcare access problems. The competition is open for entries until November 30, 2016.

"As global healthcare costs continue to rise faster than economic growth, health access will not improve without a major collaborative effort to address the gap, driven by fresh thinking," said Richard Francis, Division Head and CEO of Sandoz. "We believe that the biggest changes often come from amazing, small ideas and with the launch of Sandoz HACk we want to identify, promote and nurture creative ideas from around the world to help reimagine access to healthcare."

Despite the significant advances made in modern medicine, more than two billion people worldwide cannot access the medicines they need and more than 400 million lack access to essential health services.[1] The combined efforts of stakeholders across both public and private sectors, including the pharmaceutical industry, not-for-profit organizations and governments have made significant advances in tackling healthcare access challenges worldwide. But these large scale systemic initiatives need to be supported by community-led change, driven by innovative small scale solutions that can make a big difference. This is why Sandoz is launching Sandoz HACk, inviting people to generate novel solutions to tackle key healthcare access challenges in local communities.

Mobile technology is radically altering how care is delivered and received worldwide and the influence of mobile in healthcare is likely to continue evolving in the future. In its inaugural year, Sandoz HACk encourages today's generation of entrepreneurs and creative thinkers to enter ideas that harness mobile health technologies - M-Health - to help solve relevant local healthcare access challenges.

Sandoz HACk is open for entries from 18-35 year olds around the world. Following a robust judging process, the six finalist entries will be published on OpenIDEO - a global community of leading organizations and individuals working together to design solutions to the world's biggest challenges. Entrants' ideas will be refined and evolved in partnership with this online community before being presented to a panel of judges. Three winners will be chosen and awarded seed funding and mentorship to help bring their ideas to life.

Details of how to enter the competition and the terms and conditions can be found here:
https://www.sandoz.com/making-access-happen

Join the conversation on Twitter and Facebook using #SandozHACk.

About Sandoz
Sandoz is a global leader in generic and biosimilar pharmaceuticals. As a division of the Novartis Group, our purpose is to discover new ways to improve and extend people's lives. We contribute to society's ability to support growing healthcare needs by pioneering novel approaches to help people around the world access high-quality medicine. Our portfolio of approximately 1000 molecules, covering all major therapeutic areas, accounted for 2015 sales of USD 10.1 billion. In 2015, our products reached more than 500 million patients and we aspire to reach one billion. Sandoz is headquartered in Holzkirchen, in Germany's Greater Munich area.

About Novartis
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2015, the Group achieved net sales of USD 49.4 billion, while R&D throughout the Group amounted to approximately USD 8.9 billion (USD 8.7 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 118,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world.

1. WHO: Health in 2015; Access to Medicine Index 2015

Most Popular Now

Research Shows AI Technology Improves Pa…

Existing research indicates that the accuracy of a Parkinson's disease diagnosis hovers between 55% and 78% in the first five years of assessment. That's partly because Parkinson's sibling movement disorders...

Who's to Blame When AI Makes a Medi…

Assistive artificial intelligence technologies hold significant promise for transforming health care by aiding physicians in diagnosing, managing, and treating patients. However, the current trend of assistive AI implementation could actually...

First Therapy Chatbot Trial Shows AI can…

Dartmouth researchers conducted the first clinical trial of a therapy chatbot powered by generative AI and found that the software resulted in significant improvements in participants' symptoms, according to results...

DMEA sparks: The Future of Digital Healt…

8 - 10 April 2025, Berlin, Germany. Digitalization is considered one of the key strategies for addressing the shortage of skilled workers - but the digital health sector also needs qualified...

DeepSeek: The "Watson" to Doct…

DeepSeek is an artificial intelligence (AI) platform built on deep learning and natural language processing (NLP) technologies. Its core products include the DeepSeek-R1 and DeepSeek-V3 models. Leveraging an efficient Mixture...

Stepping Hill Hospital Announced as SPAR…

Stepping Hill Hospital, part of Stockport NHS Foundation Trust, has replaced its bedside units with state-of-the art devices running a full range of information, engagement, communications and productivity apps, to...

DMEA 2025: Digital Health Worldwide in B…

8 - 10 April 2025, Berlin, Germany. From the AI Act, to the potential of the European Health Data Space, to the power of patient data in Scandinavia - DMEA 2025...